8-K: SI-BONE Reports Record 2025 Results, Issues Strong 2026 Guidance

SI-BONE, Inc. announced record financial results for Q4 and full year 2025, achieving over 20% worldwide revenue growth and positive adjusted EBITDA, alongside new 2026 guidance and key operational updates.

Summary

• Worldwide revenue for Q4 2025 reached $56.3 million, a 15.0% increase year-over-year.
• Full year 2025 worldwide revenue was $200.9 million, growing 20.2% from 2024.
• The company achieved positive adjusted EBITDA of $5.1 million in Q4 2025 and $8.9 million for the full year 2025.
• Net loss significantly improved, reaching $1.6 million in Q4 2025 (63.3% improvement) and $18.9 million for the full year 2025 (38.8% improvement).
• SI-BONE generated positive free cash flow of $0.4 million in Q4 2025.
• For 2026, worldwide revenue is projected to be between $228.5 million and $232.5 million, representing 14% to 16% growth.
• Anshul Maheshwari, CFO, has been promoted to Chief Operating Officer, effective February 22, 2026.
• The company entered into a new lease agreement for approximately 50,485 square feet of space in San Jose, California, commencing by October 1, 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a very positive report, highlighting strong financial performance, significant improvements in profitability metrics, and clear growth catalysts for the future, despite continued net losses.

Positives

• Record worldwide revenue of $200.9 million for fiscal year 2025, a 20.2% increase year-over-year.
• Achieved positive adjusted EBITDA of $8.9 million for fiscal year 2025, a $14.0 million improvement from a loss of $5.1 million in 2024.
• Generated positive adjusted EBITDA of $5.1 million in Q4 2025, a 176.2% improvement from $1.9 million in Q4 2024.
• Net loss improved by 38.8% for fiscal year 2025 to $18.9 million and by 63.3% for Q4 2025 to $1.6 million.
• Gross margin expanded to 79.6% for fiscal year 2025, up from 79.0% in 2024.
• Positive cash flow from operations of $1.7 million and positive free cash flow of $0.4 million in Q4 2025.
• Ended Q4 2025 with $147.8 million in cash and equivalents.
• Increased U.S. physician procedures by 18% in Q4 2025, with approximately 1,640 physicians performing procedures.
• Formed a strategic partnership with Smith+Nephew for distribution of iFuse TORQ and iFuse TORQ TNT in trauma centers.
• Expanded the INTRA platform with the launch of INTRA Ti in February.
• U.S. patent portfolio for the original iFuse, including its triangular shape, extended to August 2028.
• Promotion of Anshul Maheshwari to Chief Operating Officer, leveraging his financial and operational expertise.
• Strong 2026 guidance projecting 14% to 16% worldwide revenue growth and increased positive adjusted EBITDA.

Negatives

• Despite significant improvements, the company still reported a net loss of $18.9 million for the full fiscal year 2025.
• Full year 2025 free cash flow remained negative at $(9.089) million, although it improved from $(22.922) million in 2024.
• Projected gross margin for 2026 is approximately 78%, a slight decrease from 79.6% in 2025.
• Operating expenses are expected to grow by approximately 12.5% in 2026.

Risks

• Ability to introduce and commercialize new products and indications.
• Ability to maintain favorable reimbursement for procedures using its products.
• Impact of any future economic weakness on the ability and desire of patients to undergo elective procedures.
• Ability to manage risks to its supply chain.
• Future capital requirements driven by new surgical systems requiring instrument tray and implant inventory investment.
• Pace of the re-normalization of the healthcare operating environment, including the ability and desire of patients and physicians to undergo and perform procedures.

Future Outlook

SI-BONE expects 2026 worldwide revenue to be in the range of $228.5 million to $232.5 million, implying year-over-year growth of approximately 14% to 16%. The company estimates fiscal year 2026 gross margin to be approximately 78% and operating expenses growth to be around 12.5% at the mid-point of the revenue guidance. Based on these assumptions, SI-BONE anticipates delivering increased positive adjusted EBITDA for the full year 2026, driven by favorable reimbursement dynamics, an expanding commercial footprint, and upcoming product launches.

Management Comments

• "We demonstrated the strength and scalability of our business model, delivering another year of worldwide revenue growth that exceeded 20% while expanding margins and exiting the year with positive free cash flow."
• "These results reflect disciplined execution, a differentiated platform, and durability of demand across our portfolio."
• "As we enter 2026, we have a compelling set of growth catalysts, including favorable reimbursement dynamics, expanding commercial footprint and upcoming product launches designed to deepen physician engagement and expand our reach into a sizable new market."
• "Together, these factors reinforce our confidence in SI-BONE's ability to sustain strong, profitable growth over the long term."

Industry Context

StockSavvy.ai notes that SI-BONE's strong revenue growth and transition to positive adjusted EBITDA and free cash flow in Q4 2025 demonstrate robust performance in the competitive medical device sector, particularly within the spine and orthopedic markets. The strategic partnership with Smith+Nephew for trauma centers and the expansion of the INTRA platform with INTRA Ti indicate a proactive approach to market penetration and product innovation, aligning with broader industry trends towards specialized procedural solutions and ambulatory surgical center efficiency. The patent extension for iFuse further solidifies its market position against potential competitors.

Comparison to Industry Standards

• SI-BONE's 20.2% worldwide revenue growth for FY 2025 significantly outperforms many established medical device companies, which often see single-digit growth. For example, larger players like Medtronic or Stryker typically report growth rates in the mid-to-high single digits for their established segments.
• Achieving positive adjusted EBITDA of $8.9 million for FY 2025, a $14.0 million improvement, indicates a strong trajectory towards profitability, a key benchmark for growth-stage medical technology companies. This contrasts with many smaller, high-growth med-tech firms that often remain EBITDA-negative for longer periods.
• The gross margin of 79.6% for FY 2025 is exceptionally strong and competitive within the medical device industry, often exceeding the margins of companies with less specialized or higher-volume products. For instance, companies like Zimmer Biomet or NuVasive (now part of Globus Medical) typically report gross margins in the 65-75% range.
• The expansion of the U.S. patent for iFuse to August 2028 provides a strong competitive moat, similar to how intellectual property protection is crucial for pharmaceutical companies or other specialized device manufacturers like Intuitive Surgical with its da Vinci system.

Management Changes

Stakeholder Impact

• Shareholders: Positive financial results, strong growth guidance, and improved profitability metrics are likely to increase investor confidence and potentially lead to share price appreciation. The patent extension also provides long-term value.
• Employees: Promotions of key executives like Anshul Maheshwari, Nikolas Kerr, and Jeff Zigler indicate internal growth opportunities and a stable leadership team. The new lease agreement suggests potential for expanded operations and workforce.
• Customers (Physicians/Hospitals): New product launches (INTRA Ti) and strategic partnerships (Smith+Nephew) offer expanded procedural solutions and broader access to SI-BONE's technologies, potentially improving patient outcomes.
• Suppliers: Increased commercial activity and R&D investments suggest continued or increased demand for components and services.
• Creditors: Improved financial health, positive adjusted EBITDA, and positive free cash flow in Q4 2025 enhance the company's creditworthiness.

Next Steps

• Commencement of new lease agreement by October 1, 2026.
• Continued expansion of commercial footprint.
• Upcoming product launches designed to deepen physician engagement and expand market reach.
• Conference call to discuss Q4 2025 financial results on February 23, 2026, at 4:30 P.M. Eastern Time.
• Filing of the full text of the new lease agreement as an exhibit to the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

Key Dates

Recommendation

The filing presents exceptionally strong financial performance, with record revenue growth exceeding 20% for the full year 2025, a significant turnaround to positive adjusted EBITDA, and positive free cash flow in Q4 2025. The 2026 guidance projects continued robust growth (14-16% revenue) and further improvements in profitability. Strategic operational advancements, including a major partnership with Smith+Nephew, new product launches, and a patent extension, solidify its market leadership and future growth catalysts. The promotion of a seasoned CFO to COO also strengthens the management team. These factors collectively indicate a company with strong momentum, a clear growth trajectory, and improving financial health, making it a compelling investment opportunity.

Keywords

SI-BONE, SIBN, Medical Devices, Spine Surgery, Sacroiliac Joint Fusion, iFuse, INTRA Ti, Orthopedics, Financial Results, Earnings, Revenue Growth, Adjusted EBITDA, Cash Flow, SEC Filing, 8-K, Corporate Governance, Management Change, Lease Agreement, Smith+Nephew, Trauma Centers, Patent Extension